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fractions) Adaptive Radiotherapy (ART) approach delivering a 
concomitant boost to the MRI-based residual tumour during 
the last 6 fractions. 
Materials and Methods: T3/T4N0 or N+ rectal 
adenocarcinoma patients (pts) were enrolled in an 
observational trial. Concomitant chemotherapy consisted of 
Oxaliplatin 100mg/m2 on days -14, 0, +14, and 5-FU 
200mg/m2/day from day -14 to the end of radiotherapy (day 
0 is the start of radiotherapy). Radiotherapy consisted in the 
delivery of 41.4Gy in 18 fractions (fr) (2.3 Gy/fr) with 
Tomotherapy to the tumor and regional lymph-nodes (PTV) 
defined on CT/MRI imaging. After 9 fr, CT and MRI were 
repeated for the planning of the adaptive phase: PTVadapt was 
generated by adding a 5mm margin to the residual tumour 
visible on MRI images. In the last 6 fr, a boost of 3.0 Gy/fr 
(total dose: 45.6 Gy in 18 fr) was delivered to PTVadapt while 
concomitantly delivering 2.3 Gy/fr to PTV outside PTVadapt. 
Data regarding acute toxicity and outcome were analyzed. 
Results: From September 2009 to April 2014, 50 pts 
completed the preoperative treatment and were evaluable. 
No G4 toxicity occurred: the G3 toxicity was gastrointestinal 
only: diarrhoea in 9/50 pts (18%), and proctitis in 2/50 (4%). 
Diarrhoea started before the adaptive phase in all cases and 
all affected patients were women. Two pts achieved 
complete response (cCR) and refused surgery, 1 pt was lost, 1 
pt had early distant progression. Forty-six pts underwent 
surgery (43 R0, 3 R1): thirteen pts (28 %) had pathological 
complete response (pCR); 22/46 (47%) showed TRG3 
response: 13/46 (28%) and 6/46 (13%) had ≤5%, and 6-10% 
residual viable cells, respectively. Regarding the two patients 
with cCR who refused surgery, one is still cCR after 54 
months while the other had local relapse and underwent 
transanal resection 1 year after treatment. Concerning 
treatment feasibility, two pts interrupted radiotherapy after 
7 and 13 fr respectively, the remaining pts (48/50=96%) 
completed the treatment, and the median duration of RT was 
25 days (22-36 days). 43/50 pts (86%) and 40/50 pts (80%) 
received the full dose of oxaliplatin and FU, respectively: 14% 
of pts received moderately reduced doses (60%-90%), and 
only two pts (4%) received less than 60% of the planned dose.  
Conclusions: This study confirms that adaptive boost strategy 
is feasible with an acceptable G3 toxicity rate and a very 
encouraging tumour response rate. The results suggest that 
there should still be room for further dose escalation with 
the aim of increasing pCR and/or cCR rates. 
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Purpose/Objective: In 2011, we build a dedicated 
Brachytherapy (BT) treatment suite, equipped with an HDR 
afterloader and a 1.5 T MR scanner. In this study, we 
evaluated in which way the MR scanner influences the 
position verification of applicator and organs at risk (OAR) 
and induces adaptive interventions during the process of 
brachytherapy for cervical cancer patients. 
Materials and Methods: We collected the data from 16 
patients (32 applications), treated with the MR compatible 
Utrecht tandem/ovoid intracavitary/interstitial applicator 
(Elekta Brachytherapy, The Netherlands) during the last year. 
The brachytherapy treatment schedule consisted of two 
applications and delivery of two HDR fractions each (7 
Gy/fr). Applicator insertion, repeated MR imaging and HDR 
dose delivery were performed in our treatment room 
equipped with a 1.5 T MRI scanner and a conventional 
afterloader (Elekta Brachytherapy, The Netherlands). 
Multiple MR scans during the process of BT were taken (see 
table). For this analysis we evaluated how often we actually 
performed direct adaptive interventions aiming at the 
reduction of uncertainties in dose delivery. Before the first 
applicator placement, MR images were taken to evaluate 
tumor extension and the need for needles. If needles were 
used, short sequence MR scans could be taken directly after 
the insertion to verify applicator and needle placement and 
allow adaptation before taking the definitive scans for 
treatment planning. Prior to dose delivery, MR scanning was 
repeated for position verification of the applicator parts in 
relation to the tumor and in order to detect anatomical 
changes of the OAR's. Adaptive interventions included 
repositioning of interstitial needles, insertion of rectal tubes 
to deflate gas or to change the position of the rectum, and 
variations in bladder filling mainly to reduce bowel dose. 
 
Results: In 18 of 25 applications with interstitial needles 
short sequence MR scans were taken to check needle position 
resulting in repositioning in 3 cases. In 10 of the 16 patients 
we did interventions with respect to the OAR's, 4 times for 
bladder and 7 times for rectum. Moreover, we better learned 
to individualize the use of rectal probes and bladder fillings: 
One year ago we left the rectal probe in place during 
irradiation but we discovered it not only deflated gas but also 
could displace the rectum position. In some cases it brought 
the rectum closer into the high dose areas. This resulted in a 
change of procedure. Nowadays we usually insert the probe 
for deflation and then remove it before scanning and 
irradiation. 
Conclusions: Having a combined 1,5 T MRI/HDR treatment 
room makes it possible to perform position verifications and 
adaptive interventions that helps to reduce uncertainties in 
brachytherapy and to deliver the prescribed dose as accurate 
as possible according to plan.  
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Purpose/Objective: Volumetric modulated arc therapy 
(VMAT) was demonstrated to be feasible for radiosurgical 
treatment of multiple cranial metastases (MCM). The pitch 
and roll inclusions of 107 brain patients treated in our 
institute on the PerfectPitch™ 6 degrees of freedom couch 
revealed 65.5% and 31.8% had pitch and/or roll 
compensations greater than 1° and 2°. We have investigated 
the dosimetric consequences of inaccurate pitch and roll 
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rotations positioning during the treatment of MCM using 
VMAT. 
Materials and Methods: Eight treatments of MCM were 
randomly selected from the internal database. These were 
re-planned for single and multiple isocenters (S-iso; M-iso) 
VMAT. The prescription was set to 18Gy at 99% of target 
volume. Paddick conformity index (CI), V100%, V90% for 
target; V4.5Gy, V9Gy, V12Gy for body; beam-on and door-to-
door times were analyzed. For each plan, three shifts (0.5°, 
1°, 2°) were applied for pitch and roll for each isocenter, 
simulating incorrect patient repositioning (1°, 2°) and 
involuntary motion during the delivery (0.5°). The shifted 
plans were recalculated with the same monitor units and 
compared to the reference ones in terms of reduction in 
target volume receiving 90% and 100% of the prescription 
dose. 
Results: A total of 43 metastases were evaluated. No 
significant differences were found in terms of CI between the 
two approaches. M-iso showed significant lower median 
V4.5Gy and V9Gy with respect to S-iso, while S-iso resulted in 
reduced beam on time (7.8±2.8 min vs. 10.4±3.2 min) and 
significant door-to-door time (16.3±2.7 min vs. 27.4±6.2 
min). Concerning the rotated plans, there was a worsening 
with rotation increasing, with median V100% reduction for 2° 
rotations of 22.5% and 2.7% for, respectively, S-iso and M-iso. 
Figure 1 reports the full data analysis on V90% and V100% in 
terms of volume loss. 
 
Figure 1: Delta volume loss for target V90% and V100% in 
function of pitch and roll rotations. 
Conclusions: Adjustments in all six dimensions, including 
unconventional pitch and roll rotations, are fundamental for 
MCM. S-iso reducing delivery time is the treatment of choice 
as the patient comfort is essential for so challenging 
patients. In case of S-iso, on-line patient monitoring during 
the delivery in 6D should be performed to avoid undesirable 
target underdosage. 
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Purpose/Objective: 60-80 patients with an extremity soft 
tissue sarcoma (ESTS) are diagnosed annually in Ireland. At 
least half will require radiotherapy pre or post-operatively. 
Accurate and reproducible patient immobilisation is essential 
for safe delivery of radiotherapy to these patients. However, 
the optimal technique remains to be determined.  
Materials and Methods: Two lower limb immobilisation 
devices are compared in this prospective study. Arm A: is an 
in-house developed device, comprising of customized foot-
orfits and footrests, fixed to the treatment couch. Arm B: is a 
similar device, but has the additional ability to elevate either 
limb independently. 
Results: Preliminary results indicate Arm A is useful for 
proximal thigh/groin sites when limb separation is necessary 
and Arm B is advantageous when treating the distal/anterior 
thigh and calf.  
Arm A: 268 ConeBeamCT (CBCT) scans were analysed on 20 
patients to date. The resultant CTV-PTV margins required for 
setup uncertainty are 0.7, 0.5 and 0.6cm for X, Y, and Z 
directions respectively.  
Arm B: 159 CBCT scans were analysed on 13 patients to date. 
The resultant CTV-PTV margins required for setup uncertainty 
are 0.6, 0.5 and 0.4cm for X, Y, and Z directions 
respectively.  
The standard deviation of the systematic error 
(reproducibility of treatment position) was less for B than for 
A in all directions. Levene’s test for equality/homogeneity of 
variances showed that the variances of the two groups were 
statistically significantly unequal in the z direction (p=.011).  
Conclusions:This research is on-going. Both techniques 
satisfactorily immobilise the lower limb, however the results 
show a smaller CTV-PTV margin could be applied for those 
patients immobilised with the Arm B device. However, at 
present both devices are required. Final results of this 
research study will be available in April 2015; 
recommendations will be made regarding an optimal 
immobilisation device.  
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Purpose/Objective: In 1996 we reported that 63% of 
specimens of mastectomy performed for a unifocal cancer 
harbour other cancer foci; 80% of these foci are in other 
quadrants. In contrast, local recurrence after a lumpectomy 
occurs mainly at the site of the original tumour. Therefore, 
we hypothesized that cancer foci in other quadrants remain 
dormant even in the absence of radiation treatment to the 
whole breast [1]. This academic insight led us to develop the 
targeted intraoperative radiotherapy (TARGIT) technique 
using the Intrabeam device. In the TARGIT A randomized trial 
(n=3451) we compared risk adapted TARGIT vs. whole breast 
radiotherapy [2]. 
Materials and Methods: Randomisation occurred either 
before surgery (Prepathology stratum: TARGIT given during 
lumpectomy) or after surgery (TARGIT given as a delayed 
procedure); the main analysis found that using TARGIT during 
